Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Treatment for Prevention of Smoking Relapse
NCT00063323Phase 3Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Aug 2000
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion and nicotine in Tobacco Use Disorder (TUD) (4 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Survival abstinence rate with maintenance treatment at 48 weeks. Started Aug 2000; status: completed.
02
Drugs
bupropionnicotine
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00063323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063323.